The Latest Breaking News from BIIB

With slowing inflation, indications of slower rate hikes by the Fed beginning this month, and resilient employment growth, fundamentally strong stocks Biogen (BIIB), APA Corporation (APA), and Nathan’s Famous (NATH) seem to be good investments now. Continue reading….

Despite lingering macro issues, the biotech industry is expected to witness robust growth. Moreover, amid rising medical needs and chronic diseases, research and development in the biotech sector are expected to expand, contributing to its growth. Therefore, investors might add quality biotech stocks Gilead Sciences (GILD) and Biogen (BIIB) to…

Aggressive monetary policy tightening by the Fed and red-hot inflation have led to a broad stock market sell-off this year. However, the Fed is expected to slow the pace of rate hikes in the coming months. Therefore, it could be the right time to invest in fundamentally solid stocks Oracle…

Amid the Fed's consecutive rate hikes, the Nasdaq composite has lost more than 30% year-to-date. However, it has gained marginally over the past month. Moreover, the Fed is expected to slow down the pace of rate hikes in the upcoming terms. Therefore, we think investors could consider buying quality Nasdaq…

The Federal Reserve announced its fourth consecutive 75-bps rate hike yesterday. As the chances of the economy falling into a recession are tightening, fundamentally strong and resilient stocks Merck & Co (MRK), Biogen (BIIB), and Kroger (KR), which are rated Strong Buy in our proprietary rating system, could be safe…

Despite fears of another major interest rate hike by the Fed in response to the stubborn inflation data for September, stocks such as Microsoft (MSFT) and Biogen (BIIB) have shown remarkable stability. Hence, it may be the right time to invest in them for market-beating returns. Keep reading.

A whale with a lot of money to spend has taken a noticeably bearish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 12 strange trades.

Someone with a lot of money to spend has taken a bearish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Government initiatives to expand domestic biotech production and research and rising private investments in advancing technologies are expected to boost the industry’s prospects. While we believe biotech stocks Vertex Pharmaceuticals (VRTX) and Biogen (BIIB) could be ideal investments for the long run, fundamentally weak Timber Pharmaceuticals (TMBR) might be best…